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Background. Indicators of operative outcomes could be used to identify underperforming surgeons for support and training. The
feasibility of identifying HPB surgeons with poor operative performance (“outliers”) based on the results of pancreatic resections
is not known. Methods. A systematic review of Medline, Embase, and the Cochrane library was performed to identify studies on
pancreatic resection including at least 100 patients and published between 2004 and 2014. Proportions that lay outside the upper 95%
and 99.8% confidence intervals based on results of the systematic reviews were considered as “outliers.” Results. In total, 30 studies
reporting on 10712 patients were eligible for inclusion in this review. The average short-term mortality after pancreatic resections
was 3.1% and proportion of patients with procedure-related complications was 47.0%.None of the classification systems assessed the
long-term impact of the complications on patients. The surgeon-specific mortality should be 5 times the average mortality before
he or she can be identified as an outlier with 0.1% false positive rate if he or she performs 50 surgeries a year. Conclusions. A valid
risk prognostic model and a classification system of surgical complications are necessary before meaningful comparisons of the
operative performance between pancreatic surgeons can be made.
1. Background
Indicators of operative outcomes could be used to identify
underperforming surgeons for support and training. Pancre-
atic resection is one of the most common major operative
procedures performed by Hepato-Pancreato-Biliary (HPB)
surgeons. As the procedure is complex with a high associated
morbidity andmortality, it may be suitable for comparing the
operative performances of HPB surgeons. The major indica-
tion for pancreatic resection is pancreatic cancer, the seventh
most common cause of cancer-relatedmortality in the world,
resulting in approximately 330 000 deaths worldwide annu-
ally [1]. Pancreatic cancer is a biologically aggressive cancer,
which is relatively resistant to chemotherapy and radiother-
apy and has a high rate of local and systemic recurrence
[2–4]. In early pancreatic cancer (with no invasion of adjacent
structures such as the superior mesenteric vein, portal vein,
or superior mesenteric artery or distal metastases), surgical
resection is generally considered the only treatment with the
potential for long-term survival and possibility of cure in
people likely to withstand major surgery. The overall five-
year survival after radical resection ranges from 7% to 25%
[4–9], with a median survival of 11 to 15 months [10]. With
adjuvant chemotherapy, median survival after radical resec-
tion is increased and ranges between 14 and 24 months [11].
However, it should be noted that about half of the patients
presentingwith pancreatic cancerwill havemetastatic disease
and one-third have locally advanced unresectable disease,
leaving about 10% to 20% suitable for resection [12].
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Another major indication for pancreatic resection is
chronic pancreatitis, a condition associated with long-stand-
ing and progressive inflammation of the pancreas resulting
in destruction and replacement of pancreatic tissue with
fibrous tissue leading to exocrine pancreatic insufficiency
and endocrine pancreatic insufficiency (diabetes) [13]. The
annual incidence of chronic pancreatitis ranges from 1.5 to 7.9
per population of 100,000 [14–18]. The prevalence of chronic
pancreatitis ranges from 17 to 49 per population of 100,000
[15, 16, 18]. The annual mortality rate attributable to chronic
pancreatitis is around 1 to 4 per million people [15, 17].
There is no consensus among experts for selecting patients for
surgical management but pancreatic pain and other local
complications are the major indications for surgical treat-
ment [19]. Other indications for pancreatic resection include
ampullary cancers, distal common bile duct cancers, duode-
nal cancers, intraductal papillary mucinous neoplasm, and
neuroendocrine tumours [20–23].
Pancreatic resection is in the form of pancreaticoduo-
denectomy for cancers of the head of the pancreas, ampullary
cancers, distal common bile duct cancers, and duodenal
cancers and distal pancreatectomy for cancers of the body and
tail of the pancreas [24]. Pancreaticoduodenectomy involves
excision of the head of the pancreas and duodenum. The
two major types are the classical Whipple operation and the
pylorus preserving pancreatoduodenectomy [25]. Surgical
excision for chronic pancreatitis can be performed by pan-
creaticoduodenectomy (standardWhipple’s operation or pyl-
orus preserving pancreaticoduodenectomy) or by duodenum
preserving pancreatic head resection [19, 26]. Duodenum
preserving pancreatic head resection involves resection of
the pancreatic head without excision of duodenum. The two
major types are Beger’s operation and Frey’s procedure [26].
The latter involves a drainage procedure anastomosing the
duct in the pancreatic remnant to the jejunumby longitudinal
pancreatojejunostomy in addition to pancreatic head excision
leaving behind a cuff of pancreas on the duodenal wall [26].
In general, pancreaticoduodenectomy is performed by
open surgery, although laparoscopic pancreaticoduodenec-
tomy has been reported [27]. Laparoscopic pancreatic resec-
tion is more common for distal pancreatectomy [28]. After
resection of the body and tail of the pancreas, the cut surface
of the pancreatic remnant (pancreatic stump) is closed using
staples or sutures [29].
In England, individual surgeon’s results of surgery-related
complications are being published as part of the drive by
NHS England to improve transparency [30, 31] and to allow
patients to make informed decisions. This allows patients to
identify outliers (a consultant whose clinical outcomes data
lies outside the expected range given the national average)
[31] and make an informed decision as to whether they
would like to be treated by that particular surgeon. The
feasibility of identifying HPB surgeons with poor operative
performance based on the results of pancreatic resections is
not known but it may be the most suited for comparison as
the procedures are common and complex and are generally
associated with a high morbidity and mortality. The main
objectives of this research are to conduct a systematic review
of the recent results of pancreatic resections so that it is
possible to establish a benchmark for surgeon’s performance
based on international standards and to assess the feasibility
of comparing the results of pancreatic resections between
surgeons based on the results of the systematic review.
2. Methods
2.1. Selection of Studies. All studies that reported on pancre-
atic resections irrespective of whether they were pancreati-
coduodenectomies or distal pancreatectomy, the reason for
the pancreatic resection (cancer or benign disease), the type
of access (open or laparoscopic), the type of anastomosis
(pancreaticogastrostomy or pancreatojejunostomy), and the
postoperative care provided to the patients were included.
Only studies including at least 100 patients, published as full
texts or conference abstracts in the previous 10 years from
the search date (February 2014), and reporting one or more
of the primary outcomes (30-day or in-hospital mortality)
or secondary outcomes (12-month mortality, proportion of
people with complications, number of complications, the
classification system used to report the complications, oper-
ating time, and length of hospital stay) were included in the
review to ensure that only the recent results on a reasonable
number of patientswere included in the analysis. Studieswere
identified by searching Medline, Embase, and the Cochrane
library using the Medical Subject Headings (MeSH) search
terms “pancreatectomy,” “pancreaticoduodenectomy,” and
“pancreaticojejunostomy.” Equivalent free text search terms
were used and equivalent search strategies were used in other
databases.The search strategies are available in the Appendix.
No language restrictions were applied.
Two authors (Clare Toon and Bhavisha Virendrakumar)
independently screened titles and abstracts. Full texts were
obtained for references that at least one author identified as
potentially meeting the inclusion criteria. Further selection
was made independently by two authors (Clare Toon and
Bhavisha Virendrakumar) by reviewing the full texts. All
differences were resolved by discussion and arbitration by
another author (Kurinchi Gurusamy).
2.2. Data Collection. Data on patient characteristics includ-
ing the demographic details, case-mix (risk prognostic mod-
els or score to take into account the different anaesthetic
and surgical risks in patients), and outcomes were extracted
by two authors (Clare Toon and Bhavisha Virendrakumar)
independently. Foreign language articles were translated to
English before data extraction. When significant overlap of
patients between two or more reports was identified based
on the authors, centres, and the time period, the report that
contained maximum information with regard to the out-
comes was included for the analysis. All differences in data
extraction were resolved by discussion and arbitration by
another author (Kurinchi Gurusamy).
2.3. Meta-Analysis. Meta-analysis was performed using
StatsDirect statistical software using a random-effects model.
The summary estimates with 95% confidence intervals (CI)
have been reported. Heterogeneity was assessed by Higgin’s
𝐼-square [32] and chi-square test for heterogeneity. Despite
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exploration of heterogeneity by various subgroup analyses
including the reason for pancreatic resection (cancer versus
other causes), type of resection (pancreaticoduodenectomy
versus distal pancreatic resection), and method of access
(laparoscopic versus open access), the data available from
the studies were insufficient to allow meaningful subgroup
analyses. Publication bias was assessed by funnel plot and
Egger’s regression test [33].
2.4. Assessment of Feasibility of Comparing the Operative
Performance. The short-term mortality and complications
which would have been attributable to an individual surgeon
for a hypothetical cohort of people undergoing pancreatic
resection were calculated based on the summary estimate of
the meta-analysis, the lower quartile, and the upper quartile
of the proportions observed for these outcomes in the system-
atic review, thus extrapolating the results of themeta-analysis
to an average surgeon. The 95% and 99.8% confidence inter-
vals of these outcomes were calculated using theWilson score
method with continuity correction [34] for samples sizes of
50, 100, and 200 (approximately 1 pancreatic resection a week,
2 pancreatic resections a week, and 4 pancreatic resections
a week). Proportions that lay outside the upper 95% and
99.8% confidence limits were considered as outliers with a
one-sided false positive rate of 2.5% and 0.1%, respectively.
The 95% and 99.8% confidence limits are equivalent to the
surgeon having results which are different by two standard
deviations and three standard deviations from the average
results expected based on the data (“the benchmark”). One-
sided false positive rate was calculated since the upper limit
of the confidence interval was the main interest of the study;
that is, if surgeon-specific mortality and complications were
lower than the confidence limits, it was not of any interest
since these surgeons are better than other surgeons and there
are no concerns on their operative performance.
3. Results
3.1. Search Results. A total of 7193 references were identified
by database search. After removing duplicate citations, a total
of 6268 unique referenceswere identified. Full textwas sought
for 41 references [20–23, 35–71]. A total of 6 full texts were
excluded (4 studies had less than 100 patients in total [66–
69]; one reference was a comment on an excluded article
[70]; and one study did not contain any outcomes included
in this review [71]). Five references were duplicate reports of
other studies or contained a significant proportion of patients
included in other reports [61–65].Data from these studieswas
not included in the analysis to avoid the same patients being
countedmultiple times. In total, 30 studies reporting on 10712
patients were eligible for inclusion in this review [20–23, 35–
60]. The reference flow is shown in Figure 1.
3.2. Characteristics of Included Studies. The number of
patients included in each study, the number and proportion
of patients with malignancy, the mean age of patients, the
number and proportion of female patients, and different
groups within the cohort as reported by the study authors
have been tabulated in Table 1. The number of patients
included in each study varied from 100 to 2610 patients.Three
studies included only patients with chronic pancreatitis [36,
38, 53]. One study included only patients with malignancy
[37]. The remaining studies included various proportions of
patients with malignancy. The mean age of patients reported
in the studies ranged from 42 years to 68 years. Case-mix
was assessed using surgical Apgar score (SAS) in one study
[39]. None of the remaining studies reported any adjustment
for case-mix. The surgical details of patients in terms of
the surgeries and the surgical access included in the studies
have been tabulated in Table 2. Only three studies included
patients undergoing laparoscopic pancreatic resection [20,
22, 41]. It is likely that most of the patients or all the patients
in the other studies underwent open pancreatic resection.
3.3. Outcomes
3.3.1. Short-Term Mortality. Short-term mortality (30-day or
in-hospital mortality) was reported in 21 studies including
6727 patients [21, 23, 35, 36, 38, 39, 41, 42, 44–48, 50–55, 58].
The 30-day or in-hospital mortality ranged between 0.6%
and 10.6% (lower quartile = 1.6%; upper quartile = 4.7%).
The mortality proportions in individual studies are shown
in Figure 2. The average mortality was 3.1% (95% CI 2.4% to
3.9%; 𝐼2 = 59.6%). There was no evidence of publication bias
by Egger’s regression test (𝑃 = 0.1866).
Depending upon the proportion of short-term mortality
used (the meta-analysis summary estimate, lower quartile, or
upper quartile), sample size (50, 100, or 200), and the false
positive rate (2.5% versus 0.1% for a surgeon to be wrongly
identified as an outlier), a surgeon will be called an outlier
only when the surgeon-specific mortality is several times the
averagemortality (Table 3). For example, the surgeon-specific
mortality should be more than 5 times the average mortality
before he or she can be identified as an outlier with 0.1%
false positivity rate (i.e., results lie outside three standard
deviations of the average results expected from a surgeon) if
he or she performs 50 surgeries a year.
3.3.2. 12-Month Mortality. Twelve-month mortality was re-
ported in 7 studies including 1549 patients [22, 36, 40, 49,
56, 57, 59]. The 12-month mortality ranged between 0.0%
and 8.2% (lower quartile = 0.9%; upper quartile = 3.3%).
The mortality proportions in individual studies are shown in
Figure 3. The average mortality was 2.2% (95% CI 0.7% to
4.5%; 𝐼2 = 83.7%). There was no evidence of publication bias
by Egger’s regression test (𝑃 = 0.1174).
3.3.3. Complications. Complications were reported variably
in different studies. Five studies reported complications using
the Clavien-Dindo method [72, 73] of classification of com-
plications [20, 37, 39, 48, 60]. One study used the Accordion
severity grading system [74] of classification of complications
[22]. Two studies used “common terminology criteria for
adverse events” system [75] of classification of complications
[50, 57].The remaining studies did not use any specific system
of classification of complications.
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Figure 1: Reference flow. Reference flow showing the study selection [77].
The proportion of people with complications was re-
ported in 23 studies including 6712 patients [20, 21, 23, 35–
41, 43, 45–50, 52, 54–57, 60]. The proportion of people
with complications ranged between 3.3% and 100.0% (lower
quartile = 38.3%; upper quartile = 53.4%). The proportions
of people with complications in individual studies are shown
in Figure 4. The average proportion of people with compli-
cations was 47.0% (95% CI 36.0% to 59.0%; 𝐼2 = 98.9%).
There was significant publication bias as denoted by Egger’s
regression test (𝑃 = 0.0037) with the funnel plot suggesting
that studies with lower complication proportions were more
likely to be published.
With regard to comparing the performance of surgeons,
a surgeon will be identified as an outlier with 0.1% false
positive rate when the proportion of patients who develop
complications following surgery by himor her is 1.4 times that
of the average even if he or she performs 50 surgeries a year
as shown in Table 3.
The number of complications (as opposed to the propor-
tion of people with complications) was reported in 18 studies
including 4763 patients [22, 35, 37, 38, 40, 42, 44–49, 52, 54,
55, 57–59]. The number of complications per 100 patients
ranged between 40 and 132 (lower quartile = 61 per 100
patients; upper quartile = 95 per 100 patients). The numbers
of complications per 100 patients in individual studies are
shown in Figure 5. The average number of complications per
100 patients was 80 (95% CI 70 to 90; 𝐼2 = 94.3%). There
was no evidence of publication bias by Egger’s regression test
(𝑃 = 0.4189).
3.3.4. Operating Time. The average operating time was
reported as mean or median in 22 studies including 5475
patients [20–22, 36, 39–41, 44–49, 52–60]. A meta-analysis
was not performed because of insufficient data (i.e., mean
and standard deviationwere not reported adequately inmany
studies). The mean or median operating time in the studies
ranged between 230 minutes and 492 minutes (median = 337
minutes; lower quartile = 279 minutes; upper quartile = 419
minutes).
3.3.5. Hospital Stay. The average hospital stay was reported
as mean or median in 24 studies including 7385 patients [20–
23, 35, 36, 38, 40–43, 45–48, 50–52, 54, 55, 57–60]. As for
operating time, meta-analysis was not performed for hospital
stay because of insufficient data.Themean ormedian hospital
stay in the studies ranged between 6 days and 31 days (median
= 15 days; lower quartile = 11 days; upper quartile = 17 days).
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Table 2: Surgery details.
Study ID Laparoscopic∗ Open∗ Whipple Pylorus preservingpancreaticoduodenectomy Distal pancreatectomy
Abu-Hilal et al. 2010 [35] Not stated Not stated Yes No No
Adams et al. 2013 [36] Not stated Not stated Not stated Not stated Not stated
Addeo et al. 2014 [37] Not stated Not stated Not stated Yes Not stated
Adham et al. 2013 [20] Yes Yes Yes Yes Yes
Alexakis et al. 2004 [38] Not stated Not stated Yes Yes No
Aranha et al. 2006 [21] Not stated Not stated Yes Yes No
Asbun and Stauffer 2012 [22] Yes Yes Yes Yes No
Assifi et al. 2012 [39] Not stated Not stated Yes Yes No
Barnett and Collier 2006 [23] Not stated Not stated Not stated Not stated Not stated
Bassi et al. 2005 [40] Not stated Not stated Not stated Yes Not stated
Beane et al. 2011 [41] Yes Yes No No Yes
Bedi et al. 2011 [42] Not stated Not stated Yes No No
Del Chiaro et al. 2012 [43] Not stated Not stated Not stated Not stated Not stated
Dong et al. 2013 [44] Not stated Not stated Not stated Not stated Not stated
El Nakeeb et al. 2013 [45] Not stated Not stated Yes Yes No
Fang et al. 2007 [46] Not stated Not stated Yes Yes Not stated
Fathy et al. 2008 [47] Not stated Not stated Yes Yes Not stated
Figueras et al. 2013 [48] Not stated Not stated Yes Yes No
Fischer et al. 2010 [49] Not stated Not stated Yes Yes Not stated
Fisher et al. 2011 [50] Not stated Not stated Yes Yes Yes
Haigh et al. 2011 [51] Not stated Not stated Yes Yes Not stated
Kleespies et al. 2009 [52] Not stated Not stated Yes Yes Not stated
Liu and Zheng 2010 [53] Not stated Not stated Not stated Not stated Not stated
Oussoultzoglou et al. 2004 [54] Not stated Not stated Yes Yes Not stated
Peng et al. 2007 [55] No Yes Yes Yes Not stated
Qin et al. 2013 [56] Not stated Not stated Not stated Not stated Not stated
Ross et al. 2013 [57] Not stated Not stated Not stated Not stated Not stated
Tran et al. 2004 [58] Not stated Not stated Yes Yes No
Wellner et al. 2012 [59] Not stated Not stated Yes Yes Not stated
Williams et al. 2009 [60] Not stated Not stated Yes Yes Not stated
∗It is likely that the studies that do not report on whether the surgeries were performed by open or laparoscopic method are likely to include open access
surgeries.
4. Discussion
In this systematic review and meta-analysis, the recent
results of pancreatic resections have been reviewed. Despite
significant advances in anaesthetic and surgical techniques in
the recent years, pancreatic resection remains amajor surgery
with significant risk of complications and mortality. The
average 30-day or in-hospitalmortality after pancreatic resec-
tion was approximately 3% (Figure 2) and approximately
47% of patients undergoing pancreatic resection develop
one or more complications (Figure 4). However, there was
significant variation in the mortality and the complications
as evidenced by the 𝐼2 values which demonstrated substantial
statistical heterogeneity.The average 12-month mortality was
2.2% (Figure 3) which was less than the average 30-day
mortality of 3.1%. This is not clinically possible but was
observed in this systematic review because of different studies
being included for the different time points. This is further
evidence of heterogeneity in mortality between the studies.
One possible reason for this observed heterogeneity in
the results is the inclusion of different types of surgeries in
different studies. Another possible reason is that the patients
included in the different studies had different comorbidi-
ties and there was variation in the technical difficulty of
surgery (“case-mix”). Use of prognostic models is one of the
commonly used methods to adjust for case-mix. A number
of prognostic models are available for risk adjustment in
pancreatic resections [76], although the accuracy of these
models has not been assessed systematically. Only one of the
studies included in this review considered a risk prognostic
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Proportion meta-analysis plot (random effects)
0.00 0.05 0.10 0.15 0.20
Combined 0.0312 (0.0241, 0.0392)
Tran et al. 2004 0.0529 (0.0245, 0.0981)
Peng et al. 2007 0.0461 (0.0223, 0.0831)
Oussoultzoglou et al. 2004 0.0280 (0.0113, 0.0568)
Liu and Zheng 2010 0.1057 (0.0575, 0.1740)
Kleespies et al. 2009 0.0549 (0.0267, 0.0987)
Haigh et al. 2011 0.0288 (0.0225, 0.0362)
Fisher et al. 2011 0.0100 (0.0003, 0.0545)
Figueras et al. 2013 0.0488 (0.0181, 0.1032)
Fathy et al. 2008 0.0324 (0.0131, 0.0656)
Fang et al. 2007 0.0504 (0.0306, 0.0776)
El Nakeeb et al. 2013 0.0317 (0.0174, 0.0526)
Dong et al. 2013 0.0061 (0.0002, 0.0333)
Bedi et al. 2011 0.0161 (0.0044, 0.0408)
Beane et al. 2011 0.0087 (0.0011, 0.0311)
Barnett and Collier 2006 0.0096 (0.0002, 0.0524)
Assifi et al. 2012 0.0199 (0.0100, 0.0353)
Aranha et al. 2006 0.0152 (0.0056, 0.0327)
Alexakis et al. 2004 0.0446 (0.0147, 0.1011)
Adams et al. 2013 0.0196 (0.0024, 0.0690)
Abu-Hilal et al. 2010 0.0200 (0.0024, 0.0704)
Proportion (95% confidence interval)
Figure 2: 30-day or in-hospital mortality. The figure shows the forest plot of 30-day or in-hospital mortality. The mortality ranged between
0.6% and 10.6%. The average mortality by random-effects model was 3.1%.
model to adjust for case-mix [39]. While the authors used
surgical Apgar score as the risk prognostic model, it was not
reliable in this study [39].
Prognostic models to adjust for case-mix are essential
for comparative audit between specialists to ensure that sur-
geons are not penalised for accepting to operate on high-risk
patients where there is evidence of potential patient benefit.
In addition, adequate adjustment for the case-mix is neces-
sary to allow indirect comparison of results obtained in dif-
ferent studies.Thus, a reliable method of adjustment for case-
mix (risk prognosticmodel) is necessary for pancreatic resec-
tions.
With regard to complications, in addition to the types
of pancreatic resections and case-mix contributing to the
heterogeneity in the estimates obtained in the different stud-
ies, another reason for heterogeneity is the different methods
of classifying complications.
While the mortality rate of 3% is a high perioperative
mortality rate, it does not allow comparison of the surgical
performance as the surgeon-specificmortality has to bemore
than 5 times the average mortality before the surgeon is
identified as an outlier with 0.1% false positive rate if he or
she performs 50 pancreatic resections a year (Table 3). Fifty
pancreatic resections per year equates to an average of one
resection a week and few surgeons are likely to performmore
than this. Thus, using short-term mortality does not appear
to be a sensitive way of comparing the performance ofHPB or
pancreatic surgeons. If, on the other hand, complication rates
were used to compare surgeons, an outlier will be identified if
the proportion of patients who develop complications follow-
ing surgery by him or her is only 1.4 times the average compli-
cation rates (with 0.1% false positive rate if he or she performs
50 pancreatic resections a year). An evaluation of compli-
cation rates following pancreatic resection would therefore
8 HPB Surgery
Table 3: Identification of outliers.
Outcome and proportion Sample size Outlier (2.5% false positive) Outlier (0.1% false positive)
Mortality: meta-analysis summary (3.1%)
50 >12.2% >16.7%
100 >8.6% >11.2%
200 >6.5% >8.1%
Mortality: lower quartile (1.6%)
50 >9.9% >14.4%
100 >6.4% >9.0%
200 >4.5% >5.9%
Mortality: upper quartile (4.7%)
50 >14.4% >19.0%
100 >10.8% >13.5%
200 >8.6% >10.2%
Complications: meta-analysis summary (47.0%)
50 >60.5% >64.4%
100 >56.7% >59.6%
200 >53.9% >56.0%
Complications: lower quartile (38.3%)
50 >52.1% >56.4%
100 >48.1% >51.2%
200 >45.2% >47.4%
Complications: upper quartile (53.4%)
50 >66.5% >70.1%
100 >62.9% >65.6%
200 >60.2% >62.2%
Proportion meta-analysis plot (random effects)
0.00 0.05 0.10 0.15
Combined 0.0219 (0.0069, 0.0451)
Wellner et al. 2012 0.0172 (0.0021, 0.0609)
Ross et al. 2013 0.0100 (0.0012, 0.0357)
Qin et al. 2013 0.0120 (0.0048, 0.0246)
Fischer et al. 2010 0.0000 (0.0000, 0.0280)
Bassi et al. 2005 0.0066 (0.0002, 0.0363)
Asbun and Stauffer 2012 0.0821 (0.0522, 0.1216)
0.0490 (0.0161, 0.1107)
Proportion (95% confidence interval)
Adams et al. 2013
Figure 3: 12-month mortality. The figure shows the forest plot of 12-month mortality. The mortality ranged between 0.0% and 8.2%. The
average mortality by random-effects model was 2.2%.
allow the comparison of operative performance of surgeons
with a reasonable sensitivity. However, the major problem
with using complications as the benchmark for assessing
surgeons is that they will also depend on the case-mix of the
patient cohort. In addition, none of the current classification
systems for complications adequately distinguish between
complications that result in permanent disability as opposed
to those that do not result in permanent disability. While
some of these systems include reinterventions and require-
ment for organ support while classifying complications [72–
74], the cost implications of these individual complications to
the healthcare funder are not clear.Thus, the existing systems
of classification of complications which have been applied to
major pancreatic surgery do not appear to be patient outcome
oriented or funder oriented and cannot therefore be used as
benchmark for assessing surgical performance.
Health-related quality of life (HRQoL) using a validated
quality of life scale may be a suitable way of comparing the
long-term outcomes of surgeons but is not sensitive enough
to capture the severity of the early postoperative complica-
tions. This is because the HRQoL is usually impaired imme-
diately after major surgery and hence those developing
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Proportion meta-analysis plot (random effects)
0.0 0.2 0.4 0.6 0.8 1.0
Combined 0.47 (0.36, 0.59)
Williams et al. 2009 0.50 (0.44, 0.56)
Ross et al. 2013 0.64 (0.57, 0.71)
Qin et al. 2013 0.03 (0.02, 0.05)
Peng et al. 2007 0.31 (0.25, 0.37)
Oussoultzoglou et al. 2004 0.43 (0.37, 0.50)
Kleespies et al. 2009 0.38 (0.31, 0.45)
Fisher et al. 2011 0.44 (0.34, 0.54)
Fischer et al. 2010 0.48 (0.40, 0.57)
Figueras et al. 2013 0.64 (0.55, 0.73)
Fathy et al. 2008 0.33 (0.27, 0.40)
Fang et al. 2007 0.45 (0.40, 0.50)
El Nakeeb et al. 2013 0.26 (0.22, 0.31)
Del Chiaro et al. 2012 0.51 (0.46, 0.56)
Beane et al. 2011 0.39 (0.32, 0.45)
Bassi et al. 2005 0.34 (0.27, 0.43)
Barnett and Collier 2006 0.41 (0.32, 0.51)
Assifi et al. 2012 0.43 (0.39, 0.47)
Aranha et al. 2006 1.00 (0.99, 1.00)
Alexakis et al. 2004 0.54 (0.45, 0.64)
Adham et al. 2013 0.53 (0.46, 0.59)
Addeo et al. 2014 0.54 (0.51, 0.57)
0.47 (0.37, 0.57)
0.64 (0.54, 0.73)
Proportion (95% confidence interval)
Adams et al. 2013
Abu-Hilal et al. 2010
Figure 4: Proportion of patients with complications.The figure shows the forest plot of patients with complications.The proportion of people
with complications ranged between 3.3% and 100.0%. The average proportion of complications by random-effects model was 47.0%.
major complications shortly after surgery may not have a
significant change from the baseline (observed in people
without complications) because of the low baseline values. In
addition, measurement of long-termHRQoLmay necessitate
additional follow-up for patients resulting in additional
resource utilisation and costs. The likelihood of missing data
will increase if long-term follow-up is necessary to assess the
outcomes.
Current methods which have been suggested for identi-
fying surgeons with poor operative performance are likely to
miss a significant proportion of underperforming pancreatic
surgeons. The results of this review are applicable to other
surgeries that have similar or lower mortality such as liver
resections and colorectal surgeries. Valid risk prognostic
model and classification system of surgical complications
(which captures long-term disability to patients and the
cost implications to funder) are necessary before meaningful
comparisons of the operative performance between pancre-
atic surgeons can be made.
Appendix
A. Search Date: 22 February 2014
A.1. Medline (OvidSP): 3764
(1) exp Pancreatectomy/
(2) (pancreatectomy or pancreatectomies).ti. or (pancre-
atectomy or pancreatectomies).ab.
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Proportion meta-analysis plot (random effects)
0.000 0.005 0.010 0.015
Combined 0.008 (0.007, 0.009)
Wellner et al. 2012 0.005 (0.004, 0.006)
Tran et al. 2004 0.008 (0.007, 0.010)
0.013 (0.012, 0.015)
0.004 (0.003, 0.005)
0.007 (0.006, 0.008)
0.010 (0.009, 0.011)
0.008 (0.007, 0.010)
0.009 (0.007, 0.010)
0.006 (0.005, 0.007)
0.006 (0.006, 0.007)
0.006 (0.005, 0.007)
Dong et al. 2013 0.005 (0.004, 0.006)
Bedi et al. 2011 0.007 (0.006, 0.008)
0.007 (0.006, 0.008)
0.011 (0.010, 0.013)
0.010 (0.008, 0.012)
0.009 (0.009, 0.010)
0.012 (0.010, 0.014)
Proportion (95% confidence interval)
Ross et al. 2013
Peng et al. 2007
Oussoultzoglou et al. 2004
Kleespies et al. 2009
Fischer et al. 2010
Figueras et al. 2013
Fathy et al. 2008
Fang et al. 2007
El Nakeeb et al. 2013
Bassi et al. 2005
Alexakis et al. 2004
Addeo et al. 2014
Abu-Hilal et al. 2010
Asbun and Stauffer 2012
Figure 5: Number of complications. The figure shows the forest plot of number of complications. The number of complications per 100
patients ranged between 40 and 132. The average number of complications per 100 patients by random-effects model was 80.
(3) ((pancreas or pancreatic) adj (resection or resec-
tions)).ti. or ((pancreas or pancreatic) adj (resection
or resections or operation or operations or surgery or
surgeries)).ab.
(4) exp Pancreaticoduodenectomy/
(5) (Pancreaticoduodenectomy or pancreaticoduodenec-
tomies or duodenopancreatectomy or duodenopan-
createctomies).ti. or (Pancreaticoduodenectomy or
pancreaticoduodenectomies or duodenopancreatec-
tomy or duodenopancreatectomies).ab.
(6) ((Whipple adj (procedure or procedures or operation
or operations)) or PPPD).ti. or ((Whipple adj (pro-
cedure or procedures or operation or operations or
surgery or surgeries)) or PPPD).ab.
(7) exp Pancreaticojejunostomy/
(8) (pancreaticojejunostomy or pancreaticojejunosto-
mies or pancreaticogastrostomy or pancreaticogas-
trostomies).ti. or (pancreaticojejunostomy or pancre-
aticojejunostomies or pancreaticogastrostomy or
pancreaticogastrostomies).ab.
(9) (1) or (2) or (3) or (4) or (5) or (6) or (7) or (8)
(10) randomized controlled trial.pt.
(11) controlled clinical trial.pt.
(12) randomized.ab.
(13) placebo.ab.
(14) drug therapy.fs.
(15) randomly.ab.
(16) trial.ab.
(17) groups.ab.
(18) (10) or (11) or (12) or (13) or (14) or (15) or (16) or (17)
(19) exp animals/not humans.sh.
(20) (18) not (19)
(21) exp cohort studies/
(22) cohort∗.tw.
(23) controlled clinical trial.pt.
(24) epidemiologic methods/
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(25) limit (4) to yr = 1966–1989
(26) exp case-control studies/
(27) (case$ and control$).tw.
(28) (case$ and series).tw.
(29) (21) or (22) or (23) or (25) or (26) or (27) or (28)
(30) (20) or (29)
(31) (9) and (30)
(32) limit (31) to (humans and last 10 years)
A.2. Embase (OvidSP): 4194
(1) exp pancreas resection/
(2) (pancreatectomy or pancreatectomies).ti. or (pancre-
atectomy or pancreatectomies).ab.
(3) ((pancreas or pancreatic) adj (resection or resec-
tions)).ti. or ((pancreas or pancreatic) adj (resection
or resections or operation or operations or surgery or
surgeries)).ab.
(4) exp pancreaticoduodenectomy/
(5) (Pancreaticoduodenectomy or pancreaticoduodenec-
tomies or duodenopancreatectomy or duodenopan-
createctomies).ti. or (Pancreaticoduodenectomy or
pancreaticoduodenectomies or duodenopancreatec-
tomy or duodenopancreatectomies).ab.
(6) ((Whipple adj (procedure or procedures or operation
or operations)) or PPPD).ti. or ((Whipple adj (pro-
cedure or procedures or operation or operations or
surgery or surgeries)) or PPPD).ab.
(7) exp pancreaticojejunostomy/
(8) (pancreaticojejunostomy or pancreaticojejunosto-
mies or pancreaticogastrostomy or pancreaticogas-
trostomies).ti. or (pancreaticojejunostomy or pancre-
aticojejunostomies or pancreaticogastrostomy or
pancreaticogastrostomies).ab.
(9) (1) or (2) or (3) or (4) or (5) or (6) or (7) or (8)
(10) exp crossover-procedure/or exp double-blind proce-
dure/or exp randomized controlled trial/or single-
blind procedure/
(11) (((((random∗ or factorial∗ or crossover∗ or cross
over∗ or cross-over∗ or placebo∗ or double∗) adj
blind∗) or single∗) adj blind∗) or assign∗ or allocat∗ or
volunteer∗).af.
(12) (10) or (11)
(13) exp cohort analysis/
(14) exp longitudinal study/
(15) exp prospective study/
(16) exp follow up/
(17) cohort∗.tw.
(18) exp case control study/
(19) (case∗ and control∗).tw.
(20) exp case study/
(21) (case∗ and series).tw.
(22) (13) or (14) or (15) or (16) or (17) or (18) or (19) or (20)
or (21)
(23) (12) or (22)
(24) (9) and (23)
(25) limit (24) to (human and last 10 years)
A.3. Cochrane: 205
(#1) MeSH descriptor: [Pancreatectomy] explode all trees
(#2) (pancreatectomy or pancreatectomies)
(#3) (pancreas or pancreatic) near (resection or resections)
(#4) MeSH descriptor: [Pancreaticoduodenectomy] ex-
plode all trees
(#5) (Pancreaticoduodenectomy or pancreaticoduodenec-
tomies or duodenopancreatectomy or duodenopan-
createctomies)
(#6) ((Whipple near (procedure or procedures or opera-
tion or operations)) or PPPD)
(#7) MeSH descriptor: [Pancreaticojejunostomy] explode
all trees
(#8) (pancreaticojejunostomy or pancreaticojejunosto-
mies or pancreaticogastrostomy or pancreaticogas-
trostomies)
(#9) (#1) or (#2) or (#3) or (#4) or (#5) or (#5) or (#6) or
(#7) or (#8) from 2004 to 2014
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